Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19
15 juil. 2021 13h31 HE
|
Revive Therapeutics Ltd.
Phase 3 clinical trial ongoing with next DSMB meeting at 600 completed patients.Currently at 41 clinical sites and to engage a minimum of 50 clinical sites.Aim to complete enrollment in Q3-2021 and...
Revive Therapeutics Approved to Trade on the OTCQB Market
25 juin 2021 15h09 HE
|
Revive Therapeutics Ltd.
TORONTO, June 25, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Collaborates With University of Health Sciences Antigua To Pioneer Clinical Research of Psychedelics
17 juin 2021 08h05 HE
|
Revive Therapeutics Ltd.
TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive To Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference
14 juin 2021 17h00 HE
|
Revive Therapeutics Ltd.
TORONTO, June 14, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Partners with Supriya to Pursue EUA for Bucillamine to Treat COVID in India
08 juin 2021 08h38 HE
|
Revive Therapeutics Ltd.
TORONTO, June 08, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop Oral Psilocybin Thin Film Strip
17 mai 2021 09h24 HE
|
Revive Therapeutics Ltd.
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19
03 mai 2021 09h15 HE
|
Revive Therapeutics Ltd.
TORONTO, May 03, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, Frankfurt: 31R), a specialty life sciences company focused on the research and...
Revive Therapeutics Files for FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury
27 avr. 2021 09h17 HE
|
Revive Therapeutics Ltd.
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional Patent Application
22 avr. 2021 08h00 HE
|
Revive Therapeutics Ltd.
TORONTO, April 22, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...
Revive Reschedules Annual and Special Meeting and Provides Dial-In Information
15 avr. 2021 18h00 HE
|
Revive Therapeutics Ltd.
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of...